NCT06663111Recruiting
Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
Rituximab and Ocrelizumab in Serum With Multiple Sclerosis (ROS-MS)
Source: ClinicalTrials.gov · Last updated 29 Oct 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 31 Jan 2022
- Start date
- 15 Mar 2021
- Primary completion date
- Dec 2025
- Lead sponsor
- Haukeland University Hospital
- Diseases
- Multiple sclerosis
- NCT number
- NCT06663111
What you commit to
- Study type: Observational
- Planned participants: 60
- From 15 Mar 2021 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- \* Not willing to attend laboratory for blood sample collection at scheduled time points
Who the study is looking for
- Included in OVERLORD-MS (NCT04578639)
- Willing to attend laboratory for blood sample collection at scheduled time points
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Haukeland University Hospital, Deparment of medical biochemistry and pharmacology Coordinator of this site? Confirm its status | Bergen | Norway | Recruiting |
Related publications
- Pharmacokinetic-Pharmacodynamic Modelling of Repeated Ocrelizumab Dosing in Relapsing-Remitting Multiple Sclerosis.Clin Pharmacokinet · 2026 · PMID 42663866
This page is information, not medical advice. Discuss any trial with your doctor.